Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07457463

Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease - an Observational Study

Led by Insel Gruppe AG, University Hospital Bern · Updated on 2026-03-09

80

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

I

Insel Gruppe AG, University Hospital Bern

Lead Sponsor

U

University of Zurich

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating a new digital education and self-management program designed for people with fibrotic interstitial lung diseases (FILD). This observational study aims to see if the program is practical, acceptable, and helpful during inpatient pulmonary rehabilitation and outpatient ILD care. The study also looks at whether patients who use the program show changes in health-related outcomes compared to those who received usual care before the program was introduced. The program includes multiple web-based e-learning modules tailored to individual patient needs. Patients can access the program on smartphones, tablets, or computers during inpatient rehabilitation or outpatient clinic visits. They can discuss the program content with healthcare professionals during routine therapy sessions or follow-up appointments. Participants retain access to the digital resources after discharge, and reminders encourage ongoing engagement. Participants will complete questionnaires about their experience and health outcomes, including self-efficacy, quality of life, exercise capacity, symptoms, psychological well-being, oxygen use, rehospitalization, and survival. The study collects data over a 3 to 6 month follow-up period to assess how acceptable and feasible the program is, along with its potential impact on health. This will guide planning for a future larger trial. The study started in October 2025 and is sponsored by Insel Gruppe AG, University Hospital Bern.

CONDITIONS

Brief Title

Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of fibrotic interstitial lung disease as the main reason for pulmonary rehabilitation (Berner Reha Zentrum only)
  • Enrollment in Idiopathic Interstitial Pneumonia cohort study and agreement for further data use (Inselspital only)
  • Age 18 years or older
  • Written informed consent
Not Eligible

You will not qualify if you...

  • Cognitive inability or insufficient knowledge of German to follow informed consent or study procedures
  • Diagnosis of sarcoidosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Outpatient Treatment

Duration - 3 to 6 months

Participants who consent receive access to a blended digital education and self-management program during an ILD clinic visit. They can engage with web-based e-learning modules and discuss content during follow-up appointments supported by reminders to encourage use.

1 initial clinic visit and periodic follow-up visits over 3 to 6 months

Inpatient Treatment

Duration - Duration of rehabilitation stay plus continued access after discharge

Participants enrolled during inpatient pulmonary rehabilitation receive access to the digital education and self-management program during their rehabilitation stay. They may use the program flexibly with support from therapists and discuss topics during routine therapy sessions. Access continues after discharge.

Multiple therapy sessions during inpatient rehabilitation stay

Long-term Monitoring

Duration - 3 to 6 months

Participants are followed for 3 to 6 months to assess feasibility outcomes such as program acceptance, compliance, and patient satisfaction, as well as health-related outcomes including self-efficacy, quality of life, symptoms, psychological well-being, oxygen use, and survival.

Periodic assessments during follow-up visits

Trial Site Locations

Total: 2 locations

1

Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Bern, Switzerland, 3010

Not Yet Recruiting

2

Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, Switzerland

Heiligenschwendi, Switzerland, 3625

Actively Recruiting

Loading map...

Research Team

T

Thimo Marcin, PhD

T

Thomas Franz Riegler, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Similar Trials

Proof of Concept Study on the Efficacy of Inhaled Targeted I...

Pulmonary Arterial Hypertension (PAH)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here